Molecular therapies of colorectal cancer: Where will we go from here?

被引:1
作者
Prager G. [1 ]
机构
[1] Department of Medicine i, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna
关键词
Angiogenesis; Colorectal cancer; Targeted therapy; Tyrosine kinase receptor;
D O I
10.1007/s12254-013-0108-6
中图分类号
学科分类号
摘要
Until the late 1990's colorectal cancer had a poor prognosis with a median survival of 12 months for metastatic disease. The discovery of molecular mechanisms for malignant transformation, tumor growth, angiogenesis, and metastasis formation have opened an abundance of biologic insights and subsequent therapeutic approaches, which have led to improved prognosis in many cancers, among them colorectal cancer. While inhibition of vascular endothelial growth factor (VEGF) either by blocking antibodies or synthetic soluble receptor fragments-the so-called VEGF-traps-have been shown to be beneficial when combined with chemotherapy, blocking antibodies against the epidermal growth factor receptor (EGFR) have revealed cytotoxic activity as monotherapy or in combination with chemical agents. Recently, the tyrosine kinase inhibitor regorafenib has been shown to be beneficial as a monotherapy in the salvage treatment setting for metastatic colorectal cancer (mCRC) patients. However, as major driver mechanisms for malignant transformation in colorectal cancer have so far not been accounted, we may expect an abundance of novel therapeutic options in CRC. In this review, novel promising therapeutic approaches will be outlined. © Springer-Verlag Wien 2013.
引用
收藏
页码:215 / 219
页数:4
相关论文
共 28 条
[1]  
Kopetz S., Chang G.J., Overman M.J., Et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, pp. 3677-3683, (2009)
[2]  
Hurwitz H., Fehrenbacher L., Novotny W., Et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, pp. 2335-2342, (2004)
[3]  
Loupakis F., Cremolini C., Masi G., FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial, J Clin Oncol, 30, (2012)
[4]  
Cunningham D., Lang I., Lorusso V., Et al., Bevacizumab (bev) in combination with capecitabine (cape) for the firstline treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX), J Clin Oncol, 30, (2012)
[5]  
Bennouna J., Sastre J., Arnold D., Et al., Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial, Lancet Oncol, 14, pp. 29-37, (2013)
[6]  
Van C.E., Tabernero J., Lakomy R., Et al., Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, pp. 3499-3506, (2012)
[7]  
Van C.E., Kohne C.H., Hitre E., Et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, pp. 1408-1417, (2009)
[8]  
Douillard J.Y., Siena S., Cassidy J., Et al., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study, J Clin Oncol, 28, pp. 4697-4705, (2010)
[9]  
Sawada K., Radjabi A.R., Shinomiya N., Et al., C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion, Cancer Res, 67, pp. 1670-1679, (2007)
[10]  
Shattuck D.L., Miller J.K., Carraway III K.L., Et al., Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells, Cancer Res, 68, pp. 1471-1477, (2008)